Complement Component C3aR Antibody (14D4)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11202
Key Product Details
Species Reactivity
Mouse
Applications
Immunohistochemistry-Frozen, Flow Cytometry
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2A Clone # 14D4
Concentration
0.1 mg/ml
Product Specifications
Immunogen
RBL-2H3 transfectants expressing mouse C3aR
Clonality
Monoclonal
Host
Rat
Isotype
IgG2A
Description
Novus Biologicals Rat Complement Component C3aR Antibody (14D4) (NBP3-11202) is a monoclonal antibody validated for use in IHC and Flow. All Novus Biologicals antibodies are covered by our 100% guarantee.
Applications for Complement Component C3aR Antibody (14D4)
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Frozen
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
For immunohistochemistry and Flow Cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
0.2 um filtered solution in PBS, 0.1% BSA
Preservative
0.02% Sodium Azide
Concentration
0.1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: Complement Component C3aR
Long Name
Complement Component C3a Receptor
Alternate Names
AZ3B, C3AR, C3AR1, C3R1, Complement Component C3a R
Gene Symbol
C3AR1
Additional Complement Component C3aR Products
Product Documents for Complement Component C3aR Antibody (14D4)
Product Specific Notices for Complement Component C3aR Antibody (14D4)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...